<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Inhibrx, Inc.</title>
    <link>https://www.biospace.com/employer/2381442/inhibrx-inc</link>
    <description>Inhibrx, Inc.</description>
    <language>en-US</language>
    <lastBuildDate>Fri, 20 May 2022 11:37:06 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/2381442/inhibrx-inc.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma</title>
      <link>https://www.biospace.com/clinical-catch-up-may-16-20</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.</description>
      <pubDate>Fri, 20 May 2022 11:37:06 GMT</pubDate>
      <guid>https://www.biospace.com/clinical-catch-up-may-16-20</guid>
    </item>
    <item>
      <title>Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40</title>
      <link>https://www.biospace.com/inhibrx-announces-dosing-of-first-patient-in-phase-1-dose-escalation-study-of-inbrx-106-a-novel-hexavalent-agonist-of-ox40</link>
      <description>Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today the administration of the first dose of INBRX-106 in a Phase 1 dose-escalation clinical study.</description>
      <pubDate>Wed, 08 Jan 2020 13:06:10 GMT</pubDate>
      <guid>https://www.biospace.com/inhibrx-announces-dosing-of-first-patient-in-phase-1-dose-escalation-study-of-inbrx-106-a-novel-hexavalent-agonist-of-ox40</guid>
    </item>
    <item>
      <title>Inhibrx Announces Pricing of Initial Public Offering of Common Stock</title>
      <link>https://www.biospace.com/inhibrx-announces-pricing-of-initial-public-offering-of-common-stock</link>
      <description>Inhibrx, Inc. ("Inhibrx") (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share.</description>
      <pubDate>Wed, 19 Aug 2020 02:06:06 GMT</pubDate>
      <guid>https://www.biospace.com/inhibrx-announces-pricing-of-initial-public-offering-of-common-stock</guid>
    </item>
    <item>
      <title>Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares</title>
      <link>https://www.biospace.com/inhibrx-announces-closing-of-initial-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares</link>
      <description>Inhibrx, Inc. ("Inhibrx") (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the closing of its previously announced initial public offering of 8,050,000 shares of common stock,</description>
      <pubDate>Fri, 21 Aug 2020 20:06:04 GMT</pubDate>
      <guid>https://www.biospace.com/inhibrx-announces-closing-of-initial-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares</guid>
    </item>
    <item>
      <title>Oxford Finance Announces $10 Million Credit Facility with Inhibrx, Inc.</title>
      <link>https://www.biospace.com/oxford-finance-announces-10-million-credit-facility-with-inhibrx-inc</link>
      <description>Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide, has announced that on July 15, 2020, it closed a $10 million senior secured term loan with Inhibrx, Inc., a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.</description>
      <pubDate>Tue, 25 Aug 2020 16:26:03 GMT</pubDate>
      <guid>https://www.biospace.com/oxford-finance-announces-10-million-credit-facility-with-inhibrx-inc</guid>
    </item>
    <item>
      <title>Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences - Nov 05, 2020</title>
      <link>https://www.biospace.com/inhibrx-announces-participation-in-upcoming-investor-and-scientific-conferences-nov-05-2020</link>
      <description>Inhibrx, Inc., a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced that the Company will be presenting at the following upcoming virtual investor and scientific conferences:</description>
      <pubDate>Thu, 05 Nov 2020 21:06:28 GMT</pubDate>
      <guid>https://www.biospace.com/inhibrx-announces-participation-in-upcoming-investor-and-scientific-conferences-nov-05-2020</guid>
    </item>
    <item>
      <title>Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients</title>
      <link>https://www.biospace.com/inhibrx-announces-positive-interim-results-from-the-phase-1-trial-of-inbrx-109-in-chondrosarcoma-patients</link>
      <description>Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma.</description>
      <pubDate>Wed, 11 Nov 2020 21:16:04 GMT</pubDate>
      <guid>https://www.biospace.com/inhibrx-announces-positive-interim-results-from-the-phase-1-trial-of-inbrx-109-in-chondrosarcoma-patients</guid>
    </item>
    <item>
      <title>Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford</title>
      <link>https://www.biospace.com/inhibrx-reports-financial-results-for-the-third-quarter-2020-and-announces-amended-loan-agreement-with-oxford</link>
      <description>Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th</description>
      <pubDate>Fri, 13 Nov 2020 21:16:05 GMT</pubDate>
      <guid>https://www.biospace.com/inhibrx-reports-financial-results-for-the-third-quarter-2020-and-announces-amended-loan-agreement-with-oxford</guid>
    </item>
    <item>
      <title>Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development AgreementARESTAT™ formulated product progressing into clinical trial</title>
      <link>https://www.biospace.com/arecor-s-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreementarestat-formulated-product-progressing-into-clinical-trial</link>
      <description>Arecor Ltd announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx's proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company's patented technology, Arestat™.</description>
      <pubDate>Thu, 17 Dec 2020 08:06:03 GMT</pubDate>
      <guid>https://www.biospace.com/arecor-s-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreementarestat-formulated-product-progressing-into-clinical-trial</guid>
    </item>
    <item>
      <title>Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist</title>
      <link>https://www.biospace.com/inhibrx-announces-phase-1-dose-escalation-results-of-inbrx-106-a-novel-hexavalent-ox40-agonist</link>
      <description>Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today results from Part 1 of the Phase 1 dose escalation trial of INBRX-106, a novel hexavalent OX40 agonist, in development for the treatment of solid tumors.</description>
      <pubDate>Tue, 05 Jan 2021 14:06:07 GMT</pubDate>
      <guid>https://www.biospace.com/inhibrx-announces-phase-1-dose-escalation-results-of-inbrx-106-a-novel-hexavalent-ox40-agonist</guid>
    </item>
  </channel>
</rss>
